Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses

Journal of Clinical Pharmacology

Volumn 38, Issue 12 SUPPL., 1998, Pages

  Barbanoj, Manel J ^a   Gich, Ignasi ^a   Artigas, Remei ^b   Tost, Digna ^b   Moros, Cristina ^a   Antonijoan, Rosa M ^a   García, M Luisa ^b   Mauleón, David ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Laboratorios Menarini SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXKETOPROFEN; KETOPROFEN;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSMENORRHEA; EPISTAXIS; FEMALE; HEADACHE; HEARTBURN; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL;

EID: 0032437841     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcph.1998.38.s1.33     Document Type: Article

References (30)

1. Vane JR, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89-96.
2. Hayball PJ: Chirality and nonsteroidal anti-inflammatory drugs. Drugs 1996;52(Suppl 5):47-58.
3. Evans AM: Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications and special reference to S(+)-ibuprofen. J Clin Pharmacol 1996;36:7S-15S.
4. Wechter WJ, Bigornia AE, Murray ED, Levine BH, Joung JW: Rac-flurbiprofen is more ulcerogenic than its (S)-enantiomer. Chirality 1993;5:492-494.
5. Gleeson S, Sorbie J: Efficacy of ketoprofen in treating primary dysmenorrhea. J Can Med Assoc 1983;129:842-844.
6. Sunshine A, Olson NZ: Analgesic efficacy of ketoprofen in postpartum, general surgery and chronic cancer pain. J Clin Pharmacol 1988;28(Suppl 1):47-54.
7. Veys EM: 20 years' experience with ketoprofen. Scand J Rheumatol Suppl 1991;90:1-44.
8. Serry MM: A low-dosage ketoprofen preparation in the management of osteoarthritis of the knee joint. J Int Med Res 1980;8: 388-390.
9. Muller-Fassbender H, Reiter W, Eveld H. Open multicenter long term trial (3 years) on efficacy and tolerance of ketoprofen (Orudis capsules) in rheumatology: final assessment. Curr Ther Res 1984;36:1221-1227.
10. Fine IT: Clinical experience with ketoprofen in the management of osteoarthtitis and rheumatoid arthritis. Md Med J 1989; 38:485-488.
11. Hayball PJ, Nation RL, Bochner F: Enantioselective pharmacodynamics of the nonsteroidal anti-inflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. Chirality 1992;4:484-487.
12. Suesa N, Fernandez MF, Gutierrez M, Rufat MJ, Rotllan E, Calvo L, Mauleón D, Carganico G: Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality 1993;5:589-595.
13. Mauleón D, Artigas R, Luisa García M, Carganico G: Preclinical and clinical development of dexketoprofen. Drugs 1996; 52(Suppl 5):24-46.
14. Aberg G, Ciofalo VB, Pendleton RG, Ray G, Weddle D: Inversion of (R) to (S)-ketoprofen in eight animal species. Chirality 1995;7:383-387.
15. Gich I, Bayés M, Barbanoj MJ, Artigas R, Tost D, Mauleon D: Bioinversion of R(-)-ketoprofen after oral administration in healthy volunteers. Clin Drug Invest 1996;11:347-353.
16. Rudy AC, Liu Brater C, Hall SD: Stereoselective pharmacokinetics and inversion of (R)-Ketoprofen in healthy volunteers. J Clin Pharmacol 1998;38:3S-10S.
17. Palomer A, Cabré M, Ginesta J, Mauleón D, Carganico G: Resolution of rac-ketoprofen esters by enzymatic reactions in organic media. Chirality 1993;5:320-328.
18. Carganico G, Mauleón D, García ML: A novel arylpropionic derivative, its method of preparation and its application as an analgesic. Patent WO9411332, 1994.
19. Shumaker RC: Basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986; 17:331-348.
20. SIPHAR, SIMED: Biostatistics and Data Processing. Creteil, France, 1993.
21. Bannwarth B, Lapicque F, Netter P, Monot C, Tamisier JN, Thomas P, Royer RJ: The effect of food on the systematic availability of ketoprofen. Eur J Clin Pharmacol 1988;33:643-645.
22. Bolton S: Sample size and power. In: Pharmaceutical Statistics: Drugs and the Pharmaceutical Sciences. Vol 25. New York: Marcel Dekker. 1984;169-170.
23. Shuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharmacol 1987;15: 657-680.
24. Wijnand HP, Timmer CJ: Mini-computer programs for bioequivalence testing of pharmaceutical drug formulations in two-way crossover studies. Comput Prog Biomed 1983;17:73-78.
25. Muller N, Payan E, Lapicque F, Bannwarth B, Netter P: Pharmacological aspects of chiral nonsteroidal anti-inflammatory drugs. Fund Clin Pharmacol 1990;4:617-634.
26. Gay C, Planas E, Donado M, Martínez JM, Artigas R, Torres F, Mauleón D, Carganico G: Analgesic efficacy of low doses of dexketoprofen in the dental pain model. A randomised, double-blind, placebo-controlled study. Clin Drug Invest 1996;11:320-330.
27. Fuder H, Stiegler S, Wetzelsberger N, Wieckhorst G, Lange R, Lücker PW: Effect of buffering on pharmacokinetics of ketoprofen enantiomers in man. Br J Clin Pharmacol 1997;44:527-530.
28. Foster RT, Jamali F, Russell AS, Alballa SR: Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and repeated doses. J Pharm Sci 1988;77:70-73.
29. Evans AM: Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992;42:237-256.
30. Wechter WJ. Drug chirality: on the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates. J Clin Pharmacol 1994; 34:1036-1042.